Ibrutinib (Imbruvica®), as a single agent, is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). This indication is an extension to the original licence in the relapsed/refractory setting.

Rapid Review

Not considered cost-effective due to non-submission of full pharmacoeconomic evaluation.